HEALTH "First breakthrough" therapy for early onset Alzheimer's gets FDA approval

"This is really the first breakthrough in terms of a disease-modifying therapy. One that directly targets one of the key pathologies of Alzheimer's disease that's been approved based on a clinical benefit, so it's a really exciting breakthrough in the field," said Judith Heidebrink, a neurologist at Michigan Medicine who worked on phase II clinical trial of Leqembi.